Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
-
Spotting AI writing: how reliable are the detectors?
-
Russia not preparing for conflict with Europe, Putin says
-
French youth await pope after AI 'paradise of machines' warning
-
Trump's photo of Xi greeting carries signs of AI
-
Man City found guilty of Premier League charges, set to appeal: reports
-
Six missing after building blast in historic Athens district
-
Embolo follows Xhaka out of Swiss squad over fake Covid documents
-
Millions in US northeast brace for powerful storm
-
Trump, Xi inspect founding documents of US democracy to close summit
-
Assefa seeks 'better than my best' at Berlin marathon
-
'Bottle Claus': Kipchoge's 'hero' helping runners chase Berlin marathon glory
-
US court refuses to overturn Pentagon ban on Anthropic
-
Olympic medallist Samba-Mayela handed provisional doping ban
-
Verstappen and Norris blame slow cars as Mercedes tops qualifying
-
First US trial against TikTok to open Monday
-
Crowds cheer pope in Paris after AI 'paradise of machines' warning
-
Palmer misses 'too many' England games, says Tuchel
-
Teen swimmer makes Games history as Thai, Chinese sprinters win gold
-
UN refugees chief warns conditions in W.Sahara 'deteriorating'
-
Man City found guilty of 114 Premier League charges - reports
-
Antonelli 'mad' about crash in Azerbaijan qualifying
-
Concerns over 'missing' UK explorer Ranulph Fiennes
-
'Perfect lap' gives Russell pole for Azerbaijan GP as Antonelli crashes out
-
Suspected Paris killer of Argentine rugby star begs forgiveness
-
UN Security Council condemns Houthi attacks on Saudi Arabia
-
Oil prices fall on cautious hopes for US-Iran progress
-
China swimmer makes Asian Games history as Thai wins 100m sprint
-
Noskova, Muchova take Czech Republic into BJK Cup final
-
Top French literary prize drops best-selling novel over AI claims
-
Thai sprinter Puripol breaks own Asian Games record to win 100m gold
-
US 'must choose' whether to end war: Iran president
-
Russell takes pole for Azerbaijan GP, Antonelli crashes out
-
Pope warns against losing humanity in AI-driven 'paradise of machines'
-
Williams boss hails Chadwick as F1 inspiration for women
-
Pope warns against losing humanity in 'paradise of machines'
-
World No.1 Sinner delays return with China Open withdrawal
-
From FBI warning to literary acclaim: the Russian journalist who took on Putin
-
South Lebanon children return to school destroyed by Israel strike
-
China swimmer in Asian Games first as North Korea lifters reign
-
Jewish group urges Berlin far-left vote winners to tackle antisemitism
-
French literary prize removes novel from longlist after AI claims
-
European stock markets climb as oil prices drop
-
China's Zhang wins record seventh Asian Games swimming gold
-
Trump accuser E. Jean Carroll finally has her damages
-
Verstappen edges Russell in final practice in Azerbaijan
-
Germany's Havertz, Musiala ruled out of Greece match with injury
-
English, Spanish, Italian, German football leagues call for FIFA reform
-
Ireland's Gaza stance spills from Eurovision into football
-
Pope arrives in France on first official visit in 18 years
-
Welcome aboard the Costa Serena, the Asian Games floating hotel
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
L.Maurer--VB